Pliant Therapeutics, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. Its lead program, PLN-101095, is an oral small-molecule dual-selective inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors, including immune checkpoint inhibitor-refractory advanced or metastatic disease.
Company updates commonly cover Phase 1 and Phase 1b oncology data, scientific-conference presentations, combination studies with pembrolizumab, financial results, and healthcare investor-conference participation. Pliant also describes preclinical platform work using integrin receptor-binding molecules for tissue-specific delivery and internalization of drug payloads, including programs directed to skeletal muscle cells, adipocytes, and renal cells.
Pliant Therapeutics, Inc. (PLRX) reported strong progress in its fibrosis treatment pipeline, highlighting the initiation of a Phase 2a trial for PLN-74809 in idiopathic pulmonary fibrosis, along with advancements in its partnership with Novartis for PLN-1474. The company completed a successful IPO, raising $165.6 million, with an additional $10 million from Novartis. Financial results showed second-quarter related party revenue of $3.6 million and a net loss of $17 million. Pliant holds $312.5 million in cash, ensuring operational stability through 2023.